Core Viewpoint - The approval of the medical device registration certificate for the Mindray brain-computer interface transcranial magnetic stimulation device marks a significant breakthrough in advanced medical technology for the company, indicating a substantial step towards the industrial application of non-invasive brain-computer interfaces and opening new avenues for future technological expansion and revenue growth [1] Group 1 - The Jiangsu Provincial Drug Administration has granted a medical device registration certificate to Mindray for its brain-computer interface transcranial magnetic stimulation device [1] - This achievement signifies an important milestone in the field of advanced medical technology for the company [1] - The development paves the way for the practical application of non-invasive brain-computer interfaces, enhancing the company's growth potential [1]

Core Insights - The company, Mailland, has achieved a significant milestone by obtaining the medical device registration certificate for its non-invasive brain-computer interface transcranial magnetic stimulation device, becoming the first in Jiangsu Province to do so [1][2] - This achievement marks a substantial breakthrough in the field of advanced medical technology and indicates a practical step towards the industrial application of non-invasive brain-computer interfaces, opening new avenues for future technological expansion and revenue growth [1][3] Company Developments - Mailland has been actively transforming its business and iterating its technology, establishing a solid revenue base in niche medical device sectors such as pelvic floor rehabilitation and reproductive rehabilitation, while also clearly positioning itself in high-end medical technology, including brain-computer interfaces [2] - The company’s brain-computer interface product focuses on non-invasive multimodal technology, combining EEG and fNIRS signals to enhance clinical usability and signal analysis accuracy, with expectations to obtain its first medical device registration certificate by Q1 2026 [2] Industry Trends - The brain-computer interface technology is entering a critical phase of commercialization and clinical application, benefiting from national policy support, the establishment of industry standards, and continuous breakthroughs in core technologies, indicating a shift from research validation to large-scale market expansion [2] - The domestic market for brain-computer interfaces is rapidly growing, with multiple technological routes, including invasive, semi-invasive, and non-invasive methods, suggesting a future integration of medical, rehabilitation, and consumer applications [2]

Group 1 - The core viewpoint of the article highlights a significant surge in A-share market stocks related to brain-computer interface (BCI) technology, driven by recent developments in the sector [1] - Aipeng Medical reached a 20% daily limit increase, while Kefu Medical rose over 15%, indicating strong investor interest in BCI-related companies [1] - Notable stocks such as Nanjing Panda, Pulite, and Innovation Medical achieved a 10% daily limit increase, reflecting a broader trend of positive market sentiment towards BCI stocks [1] Group 2 - The article mentions that on January 6, Strong Brain Technology, a leading company in the BCI field, announced the completion of approximately 2 billion RMB in financing, marking a significant milestone for the industry [1] - This financing round is noted to be the second largest globally in the BCI sector, only behind Neuralink, which is owned by Elon Musk [1] - The financing success of Strong Brain Technology is expected to further stimulate interest and investment in the BCI market, potentially leading to more advancements and innovations in the field [1]

资金流向方面，该股今日全天主力资金净流出2391.68万元。（数据宝） 麦澜德1月7日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 机构专用 | 3191.21 | | 中信建投证券股份有限公司河北分公司 | 2204.94 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 2138.63 | | 机构专用 | 1958.92 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1161.81 | | 卖出营业部名称 | 卖出金额(万元) | | 机构专用 | 1848.78 | | 华泰证券股份有限公司总部 | 1626.55 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1544.43 | | 机构专用 | 1101.89 | | 国投证券股份有限公司广州猎德大道证券营业部 | 963.67 | （文章来源：证券时报网） 1月7日麦澜德（688273）收盘价54.86元，收盘下跌10.39%，全天换手率30.94%，振幅15.30%，成交额 6.31亿元。科创板交易公开信息显示，当日该股因日换手率达30%等上榜。 证券时 ...

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.99%, closing at 1443.39 points, with a total trading volume of 5.729 billion shares and a turnover of 309.373 billion yuan, resulting in an average turnover rate of 2.92% [1] - Among the tradable stocks on the STAR Market, 371 stocks closed higher, with 28 stocks increasing by over 10%, including Yinos, Fuxin Technology, and Anda Intelligent, which hit the daily limit [1] - The distribution of turnover rates shows that 11 stocks had turnover rates exceeding 20%, while 39 stocks had rates between 10% and 20% [1] High Turnover Stocks - The stock with the highest turnover rate was Hengkong New Materials, which closed at 62.06 yuan, up 19.99%, with a turnover rate of 41.79% and a trading volume of 1.222 billion yuan [3] - Other notable high turnover stocks included Jianxin Superconducting, which rose by 8.99% with a turnover rate of 37.03%, and Qiangyi Co., which increased by 12.55% with a turnover rate of 31.76% [3][4] Sector Analysis - In the high turnover stocks, the electronics sector had the most representation, with 63 stocks, followed by the pharmaceutical and biological sector with 23 stocks, and the national defense and military industry with 17 stocks [2] - Among the high turnover stocks, 129 stocks saw an increase, with Hengkong New Materials, Shengbang Safety, and Bibet hitting the daily limit [2] Capital Flow - A total of 99 stocks in the high turnover category experienced net inflows of main funds, with the highest net inflows recorded for Dekeli, Huahong Company, and Hengkong New Materials, amounting to 461 million yuan, 262 million yuan, and 223 million yuan respectively [2] - Conversely, the stocks with the largest net outflows included Lvdihui, Chengdu Xian Dao, and Huasheng Lithium Battery, with outflows of 318 million yuan, 142 million yuan, and 140 million yuan respectively [2] Leverage Fund Movements - Among the high turnover stocks, 107 stocks recently received net purchases from leveraged funds, with significant increases in financing balances for Qiangyi Co., Xinyuan Co., and Huahong Company, which rose by 584 million yuan, 522 million yuan, and 459 million yuan respectively [2]

Group 1 - The Sci-Tech Innovation 50 Index opened high on January 7, fluctuated within a narrow range, turned negative in the afternoon, and then rose significantly, closing at 1443.39 points with an increase of 0.99% and a total trading volume of approximately 871.3 billion yuan [1] - The Sci-Tech Innovation Composite Index rose by 1.53% on January 7, closing at 1746.72 points with a total trading volume of about 3094 billion yuan. The average increase for the 600 stocks in the Sci-Tech Innovation Board was 1.73% with an average turnover rate of 4.27% [2] - High-priced stocks generally rose while low-priced stocks showed mixed performance. Notably, component stocks and electrical equipment stocks performed strongly, while healthcare and communication equipment stocks had the largest declines [2] Group 2 - The stock with the highest trading volume was Cambrian with 94.2 billion yuan, while ST Pava had the lowest trading volume at 482.2 million yuan [3] - The stock with the highest turnover rate was Hengkang New Materials at 41.79%, while Longteng Optoelectronics had the lowest turnover rate at 0.26% [4]

Group 1 - The brain-computer interface sector in the A-share market experienced a significant decline, with multiple companies reporting substantial drops in their stock prices [1] - Major companies such as Mailland, Chengyitong, and Aipeng Medical saw declines exceeding 10%, while others like Leidi Ke and Weisi Medical dropped over 8% [1][2] - Several brain-computer interface concept stocks issued announcements indicating a cooling off, with companies like Aerospace Changfeng stating they have not actually engaged in related business activities [1] Group 2 - Mailland's stock fell by 11.09%, with a total market value of 54.43 billion [2] - Chengyitong's stock decreased by 10.91%, with a market capitalization of 6.731 billion [2] - Aipeng Medical's stock dropped by 10.39%, with a market value of 4.514 billion [2]

麦澜德 20260106 摘要 中国脑计划推动脑机接口基础研究突破，正加速产业化落地。迈安德依 托国家重点研发计划，聚焦帕金森和阿尔兹海默症等认知功能障碍，已 积累多模态生理信号采集和神经调控技术。 迈安德选择非侵入式脑机接口技术路线，虽信号精度低于侵入式，但安 全性高、适用人群广，更易于医疗场景应用。公司已开发出脑机接口手 功能系统，并在多家医院进行临床应用。 迈安德在认知功能障碍领域，通过多模态生理信号采集识别患者情感状 态，结合神经调控与认知训练，干预大脑病灶。该项目预计 2027 年结 题，并推广应用。 在精神与心身疾病方面，迈安德完善生物反馈装备，结合外周训练与中 枢刺激，提升治疗效果。公司将传统单模态脑电拓展为加近红外双模态 信号采集，实现更立体的大脑观测。 国家政策支持力度加大，如 2025 年出台的政策文件规范医疗服务价格 及耗材引进，为脑机接口行业扫清障碍。中国脑机接口领域未来发展前 景广阔，应用场景将拓展至消费和教育领域。 Q&A 请介绍一下迈安德在脑机接口领域的布局及其未来规划。 迈安德在脑机接口领域的布局主要集中在康复和盆底业务板块。我们致力于通 过脑机接口技术实现身心同治，解决许多疾 ...

Core Insights - The brain-computer interface (BCI) sector is experiencing significant growth, highlighted by the recent completion of approximately 2 billion yuan financing by Qiangnao Technology, marking it as the second-largest financing in the field globally, after Neuralink [1][2] Industry Overview - The BCI sector has become the hottest investment track in the A-share market since the beginning of 2026, with multiple stocks such as Innovation Medical, Aipeng Medical, and Xiangyu Medical achieving consecutive trading limits [1] - The industry is currently driven by both policy support and technological breakthroughs, with expectations for Neuralink's large-scale production and automated surgical solutions marking a transition from clinical validation to commercial viability [3] Company Highlights - Qiangnao Technology, founded in February 2015, focuses on non-invasive BCI technology and has received FDA and CE certifications, making it one of the largest investors in BCI R&D globally [2] - The company has launched several products, including smart bionic limbs and brain-machine intelligent sleep devices, and has been recognized by TIME magazine as one of the best inventions of the year [2] Recent Developments - On January 6, multiple BCI stocks, including Sanbo Brain Science and Maillande, issued announcements regarding abnormal trading fluctuations, warning investors of potential risks [4][5][6] - Sanbo Brain Science, while experiencing significant stock price increases, clarified that it does not engage in BCI product development, and its revenue from neuro-regulation technology is minimal [4] - Maillande and Xiangyu Medical also reported that their BCI products are still in the R&D phase and have not yet achieved significant sales impact [5][6]

Core Viewpoint - The A-share market has seen a significant pullback in several brain-computer interface (BCI) concept stocks, with notable declines among various companies [1] Group 1: Stock Performance - Companies such as 麦澜德 (Mikland) and 熵基科技 (Entropy Technology) experienced declines exceeding 10% [1] - 诚益通 (Chengyi Tong) and 雷迪克 (Redik) fell over 7% [1] - 博拓生物 (Botuo Bio) and 爱朋医疗 (Aipeng Medical) dropped more than 6% [1] - 可孚医疗 (Kefu Medical) and 翔宇医疗 (Xiangyu Medical) decreased over 5% [1] - 狄耐克 (Dinaike) and 伟思医疗 (Weisi Medical) saw declines greater than 4% [1] Group 2: Company Announcements - Multiple BCI concept stocks issued announcements indicating a cooling off in the market [1] - 航天长峰 (Aerospace Changfeng) stated that the company has not actually engaged in BCI-related business [1] - 伟思医疗 (Weisi Medical) mentioned that new products in the BCI field are still in the early stages of market cultivation [1]